237 results on '"Oesterling, Joseph E."'
Search Results
2. Hormonal Therapy of Prostate Cancer: Limitations in the Total Androgen Ablation Concept
3. DISCRIMINATION OF MEN WITH PROSTATE CANCER FROM THOSE WITH BENIGN DISEASE BY MEASUREMENTS OF HUMAN GLANDULAR KALLIKREIN 2 (HK2) IN SERUM
4. DISCRIMINATION OF MEN WITH PROSTATE CANCER FROM THOSE WITH BENIGN DISEASE BY MEASUREMENTS OF HUMAN GLANDULAR KALLIKREIN 2 (HK2) IN SERUM
5. PROSTATE SPECIFIC ANTIGEN
6. PROSTATE SPECIFIC ANTIGEN: A DECADE OF DISCOVERY-WHAT WE HAVE LEARNED AND WHERE WE ARE GOING
7. HAVE COMPLICATION RATES DECREASED AFTER TREATMENT FOR LOCALIZED PROSTATE CANCER?
8. BLADDER NECK-SPARING TECHNIQUE ADVERSELY AFFECTS ANTI-TUMOR EFFICACY OF RADICAL PROSTATECTOMY IN PATHOLOGIC T3a PROSTATE CANCER
9. THE IMPACT OF BLADDER NECK SPARING AND NERVE SPARING ON URINARY FUNCTION AND CANCER CONTROL ASSOCIATED WITH RADICAL PROSTATECTOMY
10. THE PROBABILITY OF HAVING PROSTATE CANCER GIVEN AGE, SERUM PSA, AND DRE AS DETERMINED FROM THE TYROL SCREENING PROJECT
11. Reference ranges for serum prostate-specific antigen in black and white men without cancer
12. Screening digital rectal examination and prostate cancer mortality: a population-based case-control study
13. Understanding artificial neural networks and exploring their potential applications for the practicing urologist
14. Transurethral Needle Ablation of the Prostate: A Minimally Invasive Treatment for Symptomatic Benign Prostatic Hyperplasia
15. Prostate Cancer Screening and Beliefs about Treatment Efficacy: A National Survey of Primary Care Physicians and Urologists
16. Alpha-Blockade Therapy for Benign Prostatic Hyperplasia: from a Nonselective to a More Selective Alpha1A-Adrenergic Antagonist
17. Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing
18. A PROSPECTIVE, RANDOMIZED 1-YEAR CLINICAL TRIAL COMPARING TRANSURETHRAL NEEDLE ABLATION TO TRANSURETHRAL RESECTION OF THE PROSTATE FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
19. Serum Percent–Free PSA Does Not Predict Extraprostatic Spread of Prostate Cancer
20. Biologic Variability of Prostate-Specific Antigen and its Usefulness as a Marker for Prostate Cancer: Effects of Finasteride
21. A MODEL FOR THE NUMBER OF CORES PER PROSTATE BIOPSY BASED ON PATIENT AGE AND PROSTATE GLAND VOLUME
22. Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study
23. A MODEL FOR THE NUMBER OF CORES PER PROSTATE BIOPSY BASED ON PATIENT AGE AND PROSTATE GLAND VOLUME
24. Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy
25. Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin
26. Update on the Appropriate Staging Evaluation for Newly Diagnosed Prostate Cancer
27. Update on the Appropriate Staging Evaluation for Newly Diagnosed Prostate Cancer
28. A Nationwide Survey of Practicing Urologists: Current Management of Benign Prostatic Hyperplasia and Clinically Localized Prostate Cancer
29. A Nationwide Survey of Practicing Urologists
30. The Relationship Between Prostatic Intraepithelial Neoplasia and Prostate Cancer: Critical Issues
31. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: Effects of finasteride
32. Letter from the editor
33. THE EFFECT OF PROSTATITIS, URINARY RETENTION, EJACULATION, AND AMBULATION ON THE SERUM PROSTATE-SPECIFIC ANTIGEN CONCENTRATION
34. PREFACE
35. USE OF PROSTATE-SPECIFIC ANTIGEN, GLEASON SCORE, AND DIGITAL RECTAL EXAMINATION IN STAGING PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER
36. PROSTATE-SPECIFIC ANTIGEN DENSITY
37. AGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN
38. USING PROSTATE-SPECIFIC ANTIGEN TO ELIMINATE THE STAGING RADIONUCLIDE BONE SCAN
39. MOLECULAR FORMS OF SERUM PROSTATE-SPECIFIC ANTIGEN
40. Diagnosis and Treatment of Benign Prostatic Hyperplasia: Practice Patterns of Primary Care Physicians
41. Percent Free Prostate-Specific Antigen: Entering a New Era in the Detection of Prostate Cancer
42. Autologous blood donation prior to anatomical radical retropublic prostatectomy: is it necessary?
43. Analysis and presentation
44. Letter from the Editor
45. Medical Malpractice Implications of PSA Testing for Early Detection of Prostate Cancer
46. Determination of the “reflex range” and appropriate cutpoints for percent free prostatespecific antigen in 413 men referred for prostatic evaluation using the AxSYM system
47. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to α1-antichymotrypsin in blood samples
48. The clinical usefulness of percent free-PSA
49. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy
50. Multicenter comparison of the diagnostic performance of free prostate-specific antigen
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.